{
    "root": "3ce5ef05-9736-4fd5-a6ec-25e2c1756f46",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "CLOZAPINE",
    "value": "20250321",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "LACTOSE, UNSPECIFIED FORM",
            "code": "J2B2A4N98G",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "CLOZAPINE",
            "code": "J60AR2IKIC",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3766"
        }
    ],
    "indications": {
        "text": "clozapine tablets atypical antipsychotic indicated : treatment-resistant schizophrenia . efficacy established active-controlled study . ( 1.1 , 14.1 ) reducing suicidal behavior patients schizophrenia schizoaffective disorder . efficacy established active-controlled study . ( 1.2 , 14.2 )",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "schizoaffective disorder (DOID:5418)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5418"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "starting dose : 12.5 mg daily twice daily . ( 2.2 ) cautious titration divided schedule . ( 2.2 , 5.3 ) titration : increase total daily increments 25 mg 50 mg per day , well-tolerated . ( 2.2 ) target dose : 300 mg 450 mg per day , divided doses , end 2 weeks . ( 2.2 ) subsequent increases : increase increments 100 mg less , twice weekly . ( 2.2 ) maximum daily dose : 900 mg. ( 2.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "16.1 supplied clozapine tablets , usp , 100 mg , yellow colored , round , flat faced beveled edged tablets , '347 ' debossed one side facilitated score side , available : bottles 100 ( ndc 63629-2360-1 ) child resistant caps store controlled room temperature 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ( usp ) . keep reach children . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "clozapine tablets contraindicated patients history serious hypersensitivity clozapine ( e.g . , photosensitivity , vasculitis , erythema multiforme , stevens-johnson syndrome ) component clozapine tablets [ ( 6.2 ) ] .",
    "indications_original": "Clozapine tablets are an atypical antipsychotic indicated for: Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study. ( 1.1 , 14.1 ) Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. Efficacy was established in an active-controlled study. ( 1.2 , 14.2 )",
    "contraindications_original": "Starting Dose: 12.5 mg once daily or twice daily. ( 2.2 ) Use cautious titration and divided dosage schedule. ( 2.2 , 5.3 ) Titration: increase the total daily dosage in increments of 25 mg to 50 mg per day, if well-tolerated. ( 2.2 ) Target dose: 300 mg to 450 mg per day, in divided doses, by the end of 2 weeks. ( 2.2 ) Subsequent increases: increase in increments of 100 mg or less, once or twice weekly. ( 2.2 ) Maximum daily dose: 900 mg. ( 2.2 )",
    "warningsAndPrecautions_original": "16.1 How Supplied\n                  \n                  Clozapine Tablets, USP, 100 mg, yellow colored, round, flat faced beveled edged tablets, with '347' debossed on one side and with a facilitated score on the other side, available as:\n                  \n                     Bottles of 100 (NDC 63629-2360-1) Child resistant Caps\n                  \n                  Store at controlled room temperature 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) (see USP).Keep out of reach of children.\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Clozapine tablets are contraindicated in patients with a history of serious hypersensitivity to clozapine (e.g., photosensitivity, vasculitis, erythema multiforme, or Stevens-Johnson Syndrome) or any other component of clozapine tablets\n \n  [see Adverse Reactions (\n  \n   6.2)]\n \n  .",
    "drug": [
        {
            "name": "CLOZAPINE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3766"
        }
    ]
}